Drugs / Pegylated Alfa Interferon
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00522249 | May 2007 → May 2008 | renal cell carcinoma | The Methodist Hospital Research Institute | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pegylated Alfa Interferon | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00522249 ↗ |
| Known as | PEG-Intron | “The purpose of this study is to evaluate the combination of Pegylated Alfa Interferon (PEG-Intron), Sunitinib and Tarceva to see if this drug combination delays the disease...” NCT00522249 ↗ |
| Route | Subcutaneous | “PEG-Intron administered subcutaneously” NCT00522249 ↗ |